Complications of intravenous immune globulin treatment in neurologic disease

To the Editor: We read with interest the paper by Brannagan et al.1 reporting that 59% of patients given intravenous immune globulin (IVIg) for a neurologic illness experienced some adverse effects; 4.5% suffered a major complication and 6% had asymptomatic laboratory abnormalities. Although we welcome any report that contributes to our knowledge about adverse events related to the expanding use of …